Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study-Reference-Cited by-同舟云学术

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study

Published:2013-12-16 Issue:4 Volume:30 Page:695-709
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Gattaz Wagner F.,Campos João Alberto de Oliveira,Lacerda Acioly L.T.,Henna Elaine,Ruschel Sandra Inês,Bressan Rodrigo A.,de Oliveira Irismar Reis,Rocha Fábio Lopes,Grabowski Hamilton M.,Sacomani Ernindo,Louzã Mario R.,Quevedo João,Elkis Hélio,Filho Dirceu Zorzetto,Périco Cintia de Azevedo-Marques,Lawson Fábio Lorea,Appolinário José Carlos

Publisher

Informa Healthcare

Subject

General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1185/03007995.2013.869201

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia;Brain Sciences;2023-11-10

2. Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2023-01

3. Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study;Neuropsychiatric Disease and Treatment;2016-08

4. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia;BMC Psychiatry;2016-06-01

5. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics;International Clinical Psychopharmacology;2015-11